Clinical trials
Autoimmunity clinical trials
Below are recruiting autoimmunity clinical trials, each written for real people, not researchers. We’re tracking 341 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06680388RecruitingEarly Phase 1
CD19 CAR-T for severe autoimmune diseases
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06079294Recruiting
Autoimmune encephalitis and brain glucose metabolism
This study looks at how autoimmune encephalitis affects brain metabolism using a special PET scan. It aims to better understand the condition in people who were recently diagnosed.
ParisAges 18 years+ - NCT06173076Recruiting
Study of outcomes in anti-LGI1 brain inflammation
This study follows people newly diagnosed with anti-LGI1 encephalitis (a brain inflammation) to see how well they do over time. It aims to learn more about the condition and improve care.
Hangzhou, ZhejiangAges 18–100 - NCT06464679RecruitingPhase 1
CD19 CAR NK cells for autoimmune diseases
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
ShanghaiAges 18–65 - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT03993262RecruitingPhase 2
Bortezomib for severe autoimmune encephalitis after rituximab
This Phase 2 study tests whether bortezomib can improve outcomes and safety in adults with severe autoimmune encephalitis. It focuses on people whose condition is confirmed by brain-related autoantibodies and who have already received rituximab.
München, BavariaAges 18 years+ - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06434363RecruitingPhase 1/Phase 2
Cell therapy plus tafasitamab for autoimmune diseases
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Houston, TexasAges 18 years+ - NCT06435468Recruiting
Biocollection for rare childhood-onset immune diseases
This study collects blood and tissue samples from patients with rare immune system diseases that started in childhood, and from their relatives and healthy volunteers. The goal is to build a biocollection for future research to better understand these diseases.
Bron, BronAges 1 year+ - NCT06431776RecruitingPhase 3
Inhaled molgramostim for kids with autoimmune PAP
This study tests an inhaled medicine called molgramostim for children with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. The goal is to see if the drug can improve lung function and reduce the need for whole lung lavage (a washing procedure).
MünchenAges 6–18 - NCT06381453RecruitingPhase 2
Belimumab for autoimmune hepatitis
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
Calgary, AlbertaAges 18–80 - NCT06387654Recruiting
Collection of skin samples for immune-related skin diseases
This study collects skin samples and medical information from people with skin conditions caused by their immune system. It helps researchers better understand these diseases and develop new treatments.
ToulouseAges 6–99 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT06318533RecruitingEarly Phase 1
Engineered immune cell therapy for autoimmune diseases
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
Zhenjiang, JiangsuAges 18–70 - NCT06272500Recruiting
Betaine for high gastrin in autoimmune gastritis
This trial tests if betaine hydrochloride can lower high gastrin levels caused by autoimmune gastritis. It may help people with this condition by reducing stomach-related symptoms.
Zhengzhou, HenanAges Any age - NCT06250309Recruiting
Mediterranean diet vs. Western diet for fatigue in AIH
This study tests whether a Mediterranean diet can reduce fatigue in people with autoimmune hepatitis (AIH) compared to a typical Western diet. You will receive frozen meals for a week and track your energy levels.
Indianapolis, IndianaAges 18–80 - NCT06004349Recruiting
Genetic study of autoinflammatory diseases
This study looks for genes linked to autoinflammatory diseases like VEXAS syndrome. You or your family member can join by mailing in a blood or saliva sample to help researchers better understand these conditions.
New York, New YorkAges 1 month+ - NCT06019975Recruiting
Using Brain PET Scans to Diagnose Autoimmune Encephalitis
This study uses a special brain scan (FDG-PET) to better understand autoimmune encephalitis, a condition where the immune system attacks the brain. It may help doctors improve diagnosis by comparing PET scan results with other tests you already had.
Udine, Friuli Venezia GiuliaAges Any age - NCT05810480Recruiting
Predicting steroid-dependent liver injury with blood test
This study looks at whether a specific blood marker can predict which patients with liver inflammation will need long-term steroid treatment. It may help doctors decide the best treatment for you if you have unexplained liver injury.
AachenAges Any age - NCT05750498Recruiting
Study to improve outcomes in autoimmune liver disease
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Palo Alto, CaliforniaAges Any age - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT05089227RecruitingPhase 2
Long-term apixaban to prevent clots in autoimmune hemolytic anemia
This Phase 2 trial tests whether taking long-term apixaban (a blood thinner) can prevent venous blood clots in people with autoimmune hemolytic anemia (AIHA). It may help reduce the risk of dangerous clotting events if you meet safety and risk criteria.
DijonAges 18 years+ - NCT02877706Recruiting
Registry study for newly diagnosed ITP or AIHA
This study is a registry that collects medical information from adults who are newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA), or who are starting a treatment called fosfamatinib. It can help doctors understand these conditions better and improve future care.
ToulouseAges 18 years+ - NCT03276923Recruiting
Pregnancy registry for women with autoimmune disease
This study is a pregnancy and health registry for women with autoimmune (immune system) conditions who are trying to become pregnant or are already pregnant. It helps researchers better understand pregnancy outcomes and health needs in autoimmune disease.
Durham, North CarolinaAges Any age
Hear when a new Autoimmunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmunity?
- Yes. Clin2 currently lists 341 recruiting autoimmunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.